11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia

11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia

Hyperkalemia: Pathophysiology & Electrocardiographic Progression

Potassium is the primary intracellular cation, maintained at an intracellular concentration of 140 to 150 mEq/L versus an extracellular concentration of 3.5 to 5.0 mEq/L by the active $Na^+/K^+$ ATPase pump. Under the Nernst equation, this steep chemical gradient establishes the resting membrane potential (RMP) of cardiac myocytes (approximately $-90\text{ mV}$).

When extracellular potassium rises, the ratio of intracellular to extracellular potassium decreases, causing the resting membrane potential to become less negative (hypopolarization). Initial hypopolarization moves the RMP closer to the threshold potential, temporarily increasing myocyte excitability. However, sustained hypopolarization progressively inactivates fast voltage-gated sodium channels, depressing phase 0 of the cardiac action potential, slowing intraventricular conduction velocity, and accelerating phase 3 repolarization.

                     ELECTROCARDIOGRAPHIC PROGRESSION
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Serum K+ ~5.5–6.5 mEq/L: Tall, peaked, narrow, symmetrical T waves          │
  │ Serum K+ ~6.5–7.5 mEq/L: PR interval prolongation, P wave flattening/loss   │
  │ Serum K+ ~7.0–8.0 mEq/L: QRS interval widening, bundle branch blocks        │
  │ Serum K+ >8.0 mEq/L:     QRS merges with T wave ──> Sine Wave Pattern       │
  │ Terminal Phase:          Ventricular Fibrillation, PEA, or Asystole         │
  └─────────────────────────────────────────────────────────────────────────────┘

---

The Hyperkalemia Treatment Triad

The pharmacotherapeutic approach to hyperkalemia is structured into three chronological phases: membrane stabilization (immediate), intracellular translocation (minutes to hours), and total-body potassium elimination (hours).

                     HYPERKALEMIA PHARMACOTHERAPY TRIAD
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ PHASE 1: STABILIZE MYOCARDIAL MEMBRANE (Onset: 1–3 min; Duration: 30–60 min)│
  │   • Calcium Chloride 10% 1 g IV (Central line preferred; 270 mg elemental Ca)│
  │   • Calcium Gluconate 10% 1–3 g IV (Peripheral line safe; 90 mg Ca/g)       │
  │   • NOTE: Does NOT alter serum potassium concentration!                    │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ PHASE 2: SHIFT POTASSIUM INTRACELLULARLY (Onset: 15–30 min; Duration: 2–6 h)│
  │   • Regular Insulin 5–10 units IV + Dextrose (D50W 25–50 g)                 │
  │   • Nebulized Albuterol 10–20 mg (4x asthma dose)                           │
  │   • Sodium Bicarbonate 50 mEq IV (Only if severe metabolic acidemia)        │
  │   • Lowers serum potassium by 0.5–1.5 mEq/L temporarily                     │
  ├─────────────────────────────────────────────────────────────────────────────┤
  │ PHASE 3: ELIMINATE POTASSIUM FROM BODY (Onset: 1–4 h; Definitive Clearance) │
  │   • Loop Diuretics: Furosemide 40–80 mg IV (Renal clearance)               │
  │   • GI Cation Binders: Sodium Zirconium Cyclosilicate (Lokelma) 10 g PO TID │
  │   • Emergent Hemodialysis: Definitive extracorporeal removal (25–50 mEq/h)  │
  └─────────────────────────────────────────────────────────────────────────────┘

Phase 1: Myocardial Membrane Stabilization

Intravenous calcium does not lower serum potassium. Instead, extracellular calcium ions shift the threshold potential of cardiac myocytes to a less negative value (e.g., from $-75\text{ mV}$ toward $-65\text{ mV}$), restoring the normal physiological difference between the resting membrane potential and threshold potential. This restores sodium channel availability, normalizes phase 0 depolarization velocity, and prevents ventricular fibrillation.

• Onset & Duration: Onset is 1 to 3 minutes; duration is 30 to 60 minutes. If ECG widening persists or recurs after 5 to 10 minutes, repeat the calcium dose.
• Digoxin Toxicity Controversy: Historically, calcium was withheld in digoxin toxicity due to fear of precipitating "stone heart." Contemporary clinical evidence indicates hyperkalemia-induced conduction blocks in digitalis toxicity can be treated safely with calcium, though infusion over 20 to 30 minutes and priority administration of digoxin-specific Fab fragments remains best practice.

Phase 2: Intracellular Potassium Shifting

1. Intravenous Regular Insulin + Dextrose:
   • Mechanism: Insulin stimulates the $Na^+/K^+$ ATPase pump on skeletal muscle and hepatocytes, driving potassium into cells independently of glucose transport.
   • Dosing: Regular insulin 5 to 10 units IV push co-administered with 25 to 50 grams of Dextrose (50 to 100 mL of 50% Dextrose [D50W], or 250 to 500 mL of 10% Dextrose [D10W]). In patients with baseline blood glucose $>250\text{ mg/dL}$, dextrose may be withheld with close glucose monitoring.
   • The 5-Unit vs 10-Unit Strategy: Observational studies and small trials suggest that 5 units of regular insulin lowers potassium nearly as much as 10 units (roughly $0.6\text{ to }1.0\text{ mEq/L}$) with substantially less hypoglycemia, especially in end-stage renal disease (ESRD), low body weight or low baseline glucose. Many protocols therefore use 5 units, or 0.1 units/kg, in these patients.
   • Kinetics: Onset 15 to 30 minutes; peak 30 to 60 minutes; duration 4 to 6 hours.
   • Safety Monitoring: The half-life of regular insulin is significantly prolonged in renal dysfunction (up to 4–6 hours vs 4–9 minutes in healthy kidneys). Iatrogenic hypoglycemia peaks 2 to 4 hours post-insulin administration. Serial blood glucose must be monitored every hour for at least 4 to 6 hours.
2. Nebulized Beta-2 Agonists (Albuterol):
   • Mechanism: Stimulates beta-2 receptors, activating adenylyl cyclase, elevating intracellular cAMP, and stimulating $Na^+/K^+$ ATPase pumps.
   • Dosing: 10 to 20 mg nebulized in 4 mL normal saline over 10 to 15 minutes. This requires four to eight standard 2.5-mg nebules (4 to 8 times the standard bronchodilator dose).
   • Kinetics: Onset 15 to 30 minutes; lowers potassium by 0.5 to 1.0 mEq/L; duration 2 to 4 hours.
   • Synergy & Pitfalls: Highly synergistic when combined with insulin-dextrose (lowering potassium by $>1.2\text{ to }1.5\text{ mEq/L}$). However, up to 20% to 40% of ESRD patients are non-responders due to beta-2 receptor downregulation. Avoid monotherapy; use caution in severe ischemic coronary disease or tachycardia.
3. Sodium Bicarbonate:
   • Mechanism: Exogenous bicarbonate buffers systemic acidemia, stimulating $Na^+/H^+$ antiport and driving intracellular $K^+$ shifting.
   • Clinical Indication: Ineffective as monotherapy for acute hyperkalemia in the absence of metabolic acidosis. Indicated strictly when hyperkalemia is accompanied by severe metabolic acidosis (pH $<7.15\text{ to }7.20$, serum bicarbonate $<12\text{ mEq/L}$): administer 50 to 100 mEq IV push (one to two ampuls of 8.4%) or an isotonic infusion (150 mEq in 1 L D5W).

Phase 3: Potassium Excretion & Elimination

1. Loop Diuretics:
   • Furosemide 40 to 80 mg IV (or bumetanide 1 to 2 mg IV) enhances distal tubular sodium delivery and flow rate, accelerating urinary potassium excretion via the cortical collecting tubule. Only viable in patients with intact residual renal function and adequate hemodynamic volume.
2. Gastrointestinal Potassium Binders:
   • Sodium Zirconium Cyclosilicate (SZC / Lokelma): An inorganic non-absorbed crystal lattice that captures potassium ions in exchange for sodium and hydrogen ions throughout the gastrointestinal tract. Dosing: 10 g orally three times daily for up to 48 hours, then 5 to 10 g daily for maintenance. Onset of potassium reduction occurs within 1 hour (median time to normokalemia is 2.2 hours). Crucially, SZC does not cause bowel necrosis and is well tolerated (contains ~400 mg sodium per 5 g dose; monitor for fluid retention in severe congestive heart failure).
   • Patiromer (Veltassa): A non-absorbed spherical polymer that binds potassium in exchange for calcium in the distal colon. Dosing: 8.4 g orally once daily. Onset is 4 to 7 hours; not indicated for emergent immediate reduction, but ideal for subacute hyperkalemia. Must be separated from other oral medications by at least 3 hours.
   • Sodium Polystyrene Sulfonate (SPS / Kayexalate): A non-selective cation exchange resin. Administering SPS, particularly when co-formulated with 70% or 33% sorbitol, carries labeled warnings, reinforced by a 2009 FDA safety communication, about intestinal necrosis and colonic perforation, especially with sorbitol (this is a warning, not a boxed warning). Because onset is delayed (4 to 24 hours) and unpredictable, SPS has been largely replaced by SZC in modern emergency medicine formularies.
3. Emergent Hemodialysis:
   • The definitive intervention for severe, refractory hyperkalemia in patients with anuric ESRD or acute kidney injury. Hemodialysis clears 25 to 50 mEq of potassium per hour, lowering serum potassium by 1.0 to 1.5 mEq/L in the first 60 minutes.

---

Severe Hyponatremia: Neuro-Emergencies & Osmotic Demyelination Syndrome

Hyponatremia is defined as a serum sodium concentration $<135\text{ mEq/L}$, with severe hyponatremia defined as $<120\text{ mEq/L}$ (and profound $<110\text{ mEq/L}$). Pathophysiologic consequences are governed by the velocity of sodium decline rather than the absolute level alone.

Pathophysiology of Hyponatremic Encephalopathy

Serum sodium and its accompanying anions establish effective extracellular osmolality. When serum sodium drops, extracellular hypo-osmolality creates an osmotic pressure gradient that forces water across the blood-brain barrier through aquaporin-4 channels into astrocytic foot processes, producing cellular cerebral edema, elevated intracranial pressure, brainstem herniation, and death.

• Acute Hyponatremia ($<48\text{ hours}$): The brain has had insufficient time to adapt. Severe symptoms (seizures, coma, non-cardiogenic pulmonary edema, respiratory arrest) manifest rapidly even at sodium levels of 120 to 125 mEq/L.
• Chronic Hyponatremia ($\ge 48\text{ hours}$): Over 24 to 48 hours, brain astrocytes defend their cell volume through the active extrusion of intracellular electrolytes ($K^+$ and $Cl^-$) followed by organic osmolytes (myo-inositol, taurine, glutamate, glutamine, and choline). This regulatory volume decrease restores near-normal brain volume, rendering patients deceptively asymptomatic or only mildly confused despite profound hyponatremia ($<115\text{ mEq/L}$).

Osmotic Demyelination Syndrome (ODS / Central Pontine Myelinolysis)

When chronic hyponatremia is corrected too rapidly, the brain cannot synthesize and re-accumulate intracellular organic osmolytes as quickly as extracellular tonicity rises. Water is aggressively drawn out of astrocytes and oligodendrocytes into the hypertonic extracellular space. Dehydration of brain cells causes cell shrinkage, disruption of the blood-brain barrier, vascular endothelial damage, and apoptosis of myelin-producing oligodendrocytes.

• Clinical Presentation of ODS: Typically manifests 2 to 7 days after rapid overcorrection. Begins with dysarthria, dysphagia, and mutism, progressing to spastic quadriparesis, pseudobulbar palsy, "locked-in syndrome" (intact cognitive function with complete motor paralysis except for vertical eye movements), coma, and death.

                  OSMOTIC DEMYELINATION PATHOGENESIS
  ┌─────────────────────────────────────────────────────────────────────────────┐
  │ Chronic Hyponatremia (>=48h): Brain extrudes organic osmolytes to normalize  │
  │                               cellular volume                               │
  │                                     │                                       │
  │                       Rapid Sodium Correction (>8 mEq/L/d)                  │
  │                                     │                                       │
  │                                     ▼                                       │
  │ Hypertonic Extracellular Space draws water rapidly out of brain astrocytes   │
  │                                     │                                       │
  │                                     ▼                                       │
  │ Acute brain cell dehydration ──> Oligodendrocyte apoptosis ──> Demyelination│
  │                                     │                                       │
  │                                     ▼                                       │
  │ Locked-In Syndrome / Spastic Quadriparesis / Central Pontine Myelinolysis   │
  └─────────────────────────────────────────────────────────────────────────────┘

Emergent Management: 3% Hypertonic Saline Protocol

In any patient presenting with severe symptomatic hyponatremia with neurological compromise (status epilepticus, stupor, coma, respiratory depression, or signs of impending brain herniation):

• First-Line Bolus Therapy: Administer 100 to 150 mL of 3% Hypertonic Saline IV over 10 to 20 minutes.
• Repeat Dosing: If seizures or neurological compromise persist, repeat the 100 to 150 mL bolus up to two additional times (total of 3 boluses) at 10- to 20-minute intervals.
• Therapeutic Endpoint: Target an acute increase in serum sodium of 4 to 6 mEq/L. A 4 to 6 mEq/L elevation reduces brain water content by ~10%, rapidly relieves intracranial hypertension, terminates seizures, and reverses brainstem herniation.

The Correction Speed Limit & High-Risk Thresholds

Once acute neurological symptoms are controlled, the rate of sodium correction must strictly respect physiological boundaries:

• Standard Speed Limit: The 2013 US expert panel sets limits of 10 to 12 mEq/L in 24 hours (18 mEq/L in 48 hours) for average-risk chronic hyponatremia and 8 mEq/L in 24 hours for high-risk patients. Many institutions simply use $\le 8\text{ mEq/L}$ per 24 hours for everyone, which is the safest exam answer.
• High-Risk Threshold: In patients at elevated risk for ODS (advanced hepatic cirrhosis, chronic alcoholism, severe malnutrition, hypokalemia, or initial serum sodium $<105\text{ mEq/L}$), the target is 4 to 6 mEq/L per 24 hours, with an absolute ceiling of $\le 8\text{ mEq/L}$ per 24 hours.

Desmopressin (DDAVP) Clamp & Overcorrection Reversal Protocol

When the stimulus for antidiuretic hormone (ADH / vasopressin) release resolves—such as volume repletion in hypovolemic hyponatremia, corticosteroid administration in adrenal insufficiency, or clearance of a provoking medication in SIADH—endogenous ADH levels drop to zero. The collecting duct abruptly stops reabsorbing water, triggering massive, dilute water diuresis (aquaresis $>500\text{ mL/h}$). This causes serum sodium to surge unpredictably, exceeding the 8 mEq/L/24h speed limit and placing the patient at catastrophic risk for ODS.

1. Reactive Reversal of Overcorrection:
   • If serum sodium rises faster than 8 mEq/L in 24 hours: Immediately stop all sodium-containing fluids.
   • Administer Dextrose 5% in Water (D5W) IV at 3 to 5 mL/kg/h to replace ongoing free water losses.
   • Administer Desmopressin (DDAVP) 1 to 2 mcg IV or SQ every 6 to 8 hours to halt renal free water excretion and re-lower serum sodium back into safe boundaries.
2. Proactive "DDAVP Clamp" Strategy:
   • In patients presenting with extreme, profound chronic hyponatremia ($<110\text{ mEq/L}$), clinicians can proactively administer Desmopressin 1 to 2 mcg IV every 6 to 8 hours to deliberately fix urine concentrating ability. Simultaneously, 3% hypertonic saline is infused at a controlled rate (e.g., 15–30 mL/h) to raise serum sodium at a predictable rate of 4 to 6 mEq/L per 24 hours, entirely eliminating the risk of spontaneous uncontrolled aquaresis.